본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색
결과 내 검색 동의어 포함
결과 내 검색 동의어 포함

-

초록보기

Purpose This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.

Materials and Methods Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.

Results After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of 〉 5%.

Conclusion Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
Recent developments in the therapeutic landscape of advanced or metastatic hormone receptor-positive breast cancer Eunice Yoojin Lee, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im p. 1065-1076

Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients Wonyoung Choi, Yun-Hee Kim, Sang Myung Woo, Yebeen Yu, Mi Rim Lee, Woo Jin Lee, Jung Won Chun, Sung Hoon Sim, Heejung Chae, Hyoeun Shim, Keun Seok Lee, Sun-Young Kong p. 1077-1086

Clinicopathological characteristics of NRG1 fusion-positive solid tumors in Korean patients Yoon Jin Cha, Chung Lee, Bio Joo, Kyung A Kim, Choong-kun Lee, Hyo Sup Shim p. 1087-1095

(A) multicenter, prospective, observational study to evaluate ethanol-induced symptoms in patients receiving docetaxel chemotherapy Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn ... [et al.] p. 1096-1103

Phase Ⅱ trial of combined durvalumab plus tremelimumab with proton therapy for recurrent or metastatic head and neck squamous cell carcinoma Hana Kim, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Keunchil Park, Yong Chan Ahn, Dongryul Oh, Myung-Ju Ahn p. 1104-1112

Individualized concurrent chemotherapy for patients with stage Ⅲ–Ⅳa nasopharyngeal carcinoma receiving neoadjuvant chemotherapy combined with definitive intensity-modulated radiotherapy Pengjie Ji, Qiongjiao Lu, Xiaoqiang Chen, Yuebing Chen, Xiane Peng, Zhiwei Chen, Cheng Lin, Shaojun Lin, Jingfeng Zong p. 1113-1122

Outcomes of salvage therapy for oropharyngeal cancer recurrence following upfront radiation therapy and prognostic factors Nayeon Choi, Hack Jung Kim, Heejun Yi, Heejung Kim, Tae Hwan Kim, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Dongryul Oh, Yong Chan Ahn, Man Ki Chung p. 1123-1133

Targeting CD73 to overcomes resistance to first-generation EGFR tyrosine kinase inhibitors in non–small cell lung cancer Miso Kim, Soyeon Kim, Jeemin Yim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo p. 1134-1143

Expanded access program pralsetinib in advanced non-small cell lung cancer with rearranged during transfection (RET) gene rearrangement Youngkyung Jeon, Hyun Ae Jung, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Se-Hoon Lee p. 1144-1151

Final report on real-world effectiveness of sequential afatinib and osimertinib in EGFR positive advanced non-small cell lung cancer : updated analysis of the RESET study Taeyun Kim, Tae Won Jang, Chang Min Choi, Mi-Hyun Kim, Sung Yong Lee, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu ... [et al.] p. 1152-1170

Sublobar resection versus stereotactic body radiation therapy for clinical stage Ⅰ non-small cell lung cancer : a study using data from the Korean nationwide lung cancer registry Jeonghee Yun, Jong Ho Cho, Tae Hee Hong, Kyungmi Yang, Yong Chan Ahn, Hong Kwan Kim, Korean Association for Lung Cancer, Korea Central Cancer Registry p. 1171-1180

Clinical outcome of stereotactic body radiotherapy in patients with early-stage lung cancer with ground-glass opacity predominant lesions : a single institution experience Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Young Seob Shin, Sei Won Lee, Wonjun Ji, Chang-Min Choi, Eun Kyung Choi p. 1181-1189

Should we perform repeated re-biopsy for the detection of T790M mutation? Saerom Kim, Soo Han Kim, Jinmi Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom p. 1190-1197

Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor–positive metastatic breast cancer Seul-Gi Kim, Min Hwan Kim, Sejung Park, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Byeong Woo Park, Seung Il Kim ... [et al.] p. 1198-1209

Prognostic value of the evolution of HER2-low expression after neoadjuvant chemotherapy Youzhao Ma, Mingda Zhu, Jingyang Zhang, Minhao Lv, Xiuchun Chen, Zhenzhen Liu p. 1210-1221

Health-seeking behavior returning to normalcy overcoming COVID-19 threat in breast cancer Eun-Gyeong Lee, Yireh Han, Dong-Eun Lee, Hyeong-Gon Moon, Hyoung Won Koh, Eun-Kyu Kim, So-Youn Jung p. 1222-1230

(The) role of adjuvant chemotherapy after neoadjuvant chemoradiotherapy followed by surgery in patients with esophageal squamous cell carcinoma Seong Yong Park, Hong Kwan Kim, Yeong Jeong Jeon, Junghee Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jae Il Zo p. 1231-1239

Development and validation of models to predict lymph node metastasis in early gastric cancer using logistic regression and gradient boosting machine methods Hae Dong Lee, Kyung Han Nam, Cheol Min Shin, Hye Seung Lee, Young Hoon Chang, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sang-Hoon Ahn, Hyung-Ho Kim p. 1240-1249

(A) phase 3 randomized clinical trial to compare efficacy and safety between combination therapy and monotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10) Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi p. 1250-1260

Clinical significance of combining preoperative and postoperative albumin-bilirubin score in colorectal cancer Doyoun Kim, Jae-Hoon Lee, Eun-Suk Cho, Su-Jin Shin, Hye Sun Lee, Hwa-Hee Koh, Kang Young Lee, Jeonghyun Kang p. 1261-1269

Specific mutations in APC, with prognostic implications in metastatic colorectal cancer Huan Peng, Jun Ying, Jia Zang, Hao Lu, Xiaokai Zhao, Pengmin Yang, Xintao Wang, Jieyi Li, Ziying Gong, Daoyun Zhang, Zhiguo Wang p. 1270-1280

Differential perspectives by specialty on oligometastatic colorectal cancer : a Korean Oligometastasis Working Group’s Comparative Survey study Won Kyung Cho, Gyu Sang Yoo, Chai Hong Rim, Jae-Uk Jeong, Eui Kyu Chie, Yong Chan Ahn, Hyeon-Min Cho, Jun Won Um, Yang-Gun Suh, Ah Ram Chang, Jong Hoon Lee p. 1281-1290

ARID1A mutation from targeted ngs predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract cancer Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Beodeul Kang, Chan Kim, Hyo Sup Shim, Young Nyun Park, Sanghoon Jung, Sung Hoon Choi, Hye Jin Choi, Choong-kun Lee, Hong Jae Chon p. 1291-1302

Prevalence and risk factors of germline pathogenic variants in pancreatic ductal adenocarcinoma Kum Hei Ryu, Sunhwa Park, Jung Won Chun, Eunhae Cho, Jongmun Choi, Dong-Eun Lee, Hyoeun Shim, Yun-Hee Kim, Sung-Sik Han, Sang-Jae Park, Sang Myung Woo, Sun-Young Kong p. 1303-1312

Analysis of plasma circulating tumor DNA in borderline resectable pancreatic cancer treated with neoadjuvant modified FOLFIRINOX : clinical relevance of DNA damage repair gene alteration detection Dong-Hoon Lim, Hyunseok Yoon, Kyu-pyo Kim, Baek-Yeol Ryoo, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dae Wook Hwang, Jae Hoon Lee, Ki Byung Song, Song Cheol Kim, Seung-Mo Hong, Jaewon Hyung, Changhoon Yoo p. 1313-1320

Favorable immunotherapy plus tyrosine kinase inhibition outcome of renal cell carcinoma patients with low CDK5 expression Xianglai Xu, Ying Wang, Zhaoyi Chen, Yanjun Zhu, Jiajun Wang, Jianming Guo p. 1321-1336

TNM-based head-to-head comparison of urachal carcinoma and urothelial bladder cancer : stage-matched analysis of a large multicenter national cohort Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong p. 1337-1345

Safety and tolerability of weekly genexol-PM, a cremophor-free polymeric micelle formulation of paclitaxel, with carboplatin in gynecologic cancer : a phase Ⅰ study So Hyun Nam, Shin-Wha Lee, Young-Jae Lee, Yong Man Kim p. 1346-1354

Intensified first cycle of rituximab plus eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone with rituximab chemotherapy for advanced-stage or bulky diffuse large B-cell lymphoma : a multicenter phase Ⅱ consortium for improving survival of lymphoma (CISL) study Yu Ri Kim, Jin Seok Kim, Won Seog Kim, Hyeon Seok Eom, Deok-Hwan Yang, Sung Hwa Bae, Hyo Jung Kim, Jae Hoon Lee, Suk-Joong Oh, Sung-Soo Yoon ... [et al.] p. 1355-1362

Long-term complete remission of decitabine-primed tandem CD19/CD22 CAR-T therapy with PD-1 and BTK inhibitors maintenance in a refractory primary central nervous system lymphoma patient Rui Zou, Xiao Zhou, Hailing Liu, Peng Wang, Fan Xia, Liqing Kang, Lei Yu, Depei Wu, Zhengming Jin, Changju Qu p. 1363-1368

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차